Adcytherix gains $122m to propel ADC development
France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
Tubulis closes $361m in Series C to advance cancer treatment
Tubulis has completed a Series C financing round, securing €308m ($361m) that will primarily be directed towards advancing clinical development…
-
BioCryst to buy Astria Therapeutics for $700m in enterprise value
BioCryst Pharmaceuticals has signed a definitive agreement to buy Astria Therapeutics with a mix of cash and stock transactions. The…
-
CIPO grants patent to Palisade Bio’s PALI-2108
The Canadian Intellectual Property Office (CIPO) has awarded Palisade Bio a patent for its ileocolonic-targeted Phosphodiesterase 4, subtype B/D (PDE4…
-
J&J in talks to acquire Protagonist Therapeutics
Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as…
-
FDA approves Teva and Medincell’s bipolar I disorder treatment
Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone), a once-a-month…
-
Arthrosi gains $153m for development of gout therapy
US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is earmarked to advance the…
-
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant…
-
Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).…
-
Oragenics partners Receptor.AI for brain health candidate portfolio
Clinical-stage biotechnology company Oragenics has announced a strategic collaboration with the US-based tech bio firm Receptor.AI to expedite the development…